Sugi Predict

Sugi Predict / Compounds / Aklomide

Aklomide

Aklomide

SCHEMBL328368

NC(=O)c1ccc([N+](=O)[O-])cc1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 1.00
▸ HSD17B10 Q99714 1/20 0.58
▸ MAPT P10636 5/20 0.55
▸ GAA P10253 2/20 0.55
▸ MAPK1 P28482 2/20 0.55
▸ HTT P42858 1/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.55
▸ FLT1 P17948 1/20 0.54
▸ FLT4 P35916 1/20 0.54
▸ KDR P35968 1/20 0.54
▸ TDP1 Q9NUW8 3/20 0.53
▸ ALDH1A1 P00352 3/20 0.53
▸ CYP3A4 P08684 2/20 0.53
▸ ALOX15 P16050 1/20 0.53
▸ CASP1 P29466 1/20 0.52
▸ RAB9A P51151 3/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ TSHR P16473 1/20 0.52
▸ POLB P06746 4/20 0.51
▸ NPC1 O15118 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aklomide SCHEMBL29637033 1.00 KMT2A (1.00) KMT2AHSD17B10MAPTGAAMAPK1
Aklomide SCHEMBL29288677 0.98 KMT2A (0.97) KMT2AHSD17B10MAPTGAAMAPK1
SCHEMBL1789120 0.86 KMT2A (0.75) KMT2AHSD17B10MAPTMAPK1ALDH1A1
SCHEMBL30492573 0.85 KMT2A (0.74) KMT2AHSD17B10MAPTGAAMAPK1
SCHEMBL6890670 0.84 KMT2A (0.73) KMT2AHSD17B10MAPTGAAMAPK1
SCHEMBL231457 0.84 KMT2A (0.72) KMT2AHSD17B10MAPTGAAMAPK1
SCHEMBL752917 0.84 KMT2A (0.72) KMT2AHSD17B10MAPTGAAMAPK1
SCHEMBL6398309 0.83 KMT2A (0.71) KMT2AMAPTGAATDP1ALDH1A1
SCHEMBL8447120 0.82 KMT2A (0.70) KMT2AHSD17B10MAPTGAAMAPK1
Potassium Ion SCHEMBL11056843 0.82 KMT2A (0.70) KMT2AHSD17B10MAPTGAAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023161832-A1 MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME GARCIA SADA FERNANDO (MX) 2023-08-31 — — WO claimed
US-20230266340-A1 Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome SILTI AG (CH) 2023-08-24 — — US claimed
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2017-10-12 — — US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
EP-1506196-B1 PYRAZOLOPYRIMIDINES AS SODIUM CHANNEL INHIBITORS ICAGEN INC (US) 2012-01-18 — — EP claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 — — US claimed
US-20100075932-A1 NOVEL SALICYLIC ANILIDES HIGH POINT PHARMACEUTICALS, LLC (US) 2010-03-25 — — US claimed
US-7645791-B2 Salicylic anilides HIGH POINT PHARMACEUTICALS, LLC (US) 2010-01-12 — — US claimed
US-20090005434-A1 Novel Salicylic Anilides NOVO NORDISK A/S (DK) 2009-01-01 — — US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 — — CN claimed
US-20060121488-A1 Glutamate transport modulatory compounds and methods NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2006-06-08 — — US claimed
WO-2006020681-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OF UBIQUITIN CONJUGATING DISORDERS HYGEIA BIOLOGICAL SYSTEMS (US) 2006-02-23 — — WO claimed
US-20060035890-A1 Compounds and methods for the treatment of ubiquitin conjugating disorders AMIT BANERJEE 2006-02-16 — — US claimed
EP-1611238-A2 GLUTAMATE TRANSPORT MODULATORY COMPOUNDS AND METHODS Johns Hopkins University (US) 2006-01-04 — — EP claimed
WO-2005051894-A1 NOVEL SALICYLIC ANILIDES NOVO NORDISK A/S (DK) 2005-06-09 — — WO claimed
WO-2004076675-A2 GLUTAMATE TRANSPORT MODULATORY COMPOUNDS AND METHODS JOHNS HOPKINS UNIVERSITY (US) 2004-09-10 — — WO claimed
EP-1435930-A2 ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2004-07-14 — — EP claimed
WO-2003032969-A2 ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2003-04-24 — — WO claimed
EP-1150565-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION bioscience AG (DE) 2001-11-07 — — EP claimed
WO-2000045635-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2000-08-10 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS KMT2A 2912/4885HSD17B10 2084/4885MAPT 3694/4885
US-20090005434-A1 Novel Salicylic Anilides FABP4, ADIPOR1, ADIPOR2 KMT2A 3568/4885HSD17B10 209/4885MAPT 4415/4885
US-20100075932-A1 NOVEL SALICYLIC ANILIDES FABP4, ADIPOR1, ADIPOR2 KMT2A 3568/4885HSD17B10 209/4885MAPT 4415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.